Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).
Neutrolis has raised $23.1M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Neutrolis's investors include Morningside, Prefix Capital, PBJ Capital.
Neutrolis is headquartered in Cambridge, United States.
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).
Neutrolis is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neutrolis — Funding & Investors." VCBacked, December 3, 2021, https://www.vcbacked.co/company/neutrolis. Accessed August 14, 2026.
VCBacked. (2021). Neutrolis — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/neutrolis
{{cite web |title=Neutrolis — Funding & Investors |url=https://www.vcbacked.co/company/neutrolis |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated